Understanding the decisions of cancer clinical trial participants to enter research studies: Factors associated with informed consent, patient satisfaction, and decisional regret

被引:102
作者
Stryker, Jo Ellen
Wray, Ricardo J.
Emmons, Karen M.
Winer, Eric
Demetri, George
机构
[1] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[2] St Louis Univ, Sch Publ Hlth, Hlth Commun Res Lab, St Louis, MO 63103 USA
[3] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Cambridge, MA 02138 USA
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA
关键词
informed consent; clinical trials; decision-making; cancer;
D O I
10.1016/j.pec.2005.09.006
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: To understand the psychosocial outcomes related to decision-making processes of individuals eligible for participation in clinical trials. Methods: Individuals eligible to participate in selected clinical trials were contacted to complete two surveys; one shortly after participants were identified, and the second 6 weeks after the first survey was completed (N = 50). Measures included subjective informed consent; satisfaction with decision-making; decisional regret; and timing of consent (early versus late signers). ANOVA and correlation coefficients were used to test the relationships between variables. Results: Early signers reported themselves to be less informed about the details of their particular clinical trials than later signers (M = 81.9 versus 91.2; F = 5.5; p =.02). There was a non-significant trend for early signers to be less satisfied with their decisions than late signers. Satisfaction with decision-making and subjective informed consent were both strongly associated with later decisional regret (r = -.32 and -.30, respectively). However, there was no relationship between timing of consent and decisional regret. Conclusion: Participants who enroll in clinical trials quickly may not believe they fully understand the implications of trial participation. In general, participants who do not believe they fully understand the implications of trial participation, or who are less satisfied with their decision to enroll in the trial may ultimately feel regret about their decision to participate. Practice implications: More effort is needed to ensure that clinical trial participants fully understand the risks and benefits of participation and are satisfied with their decision to enroll in a trial prior to signing consent forms. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:104 / 109
页数:6
相关论文
共 25 条
[1]  
[Anonymous], 2003, COCHRANE DATABASE SY
[2]   Validation of a decision regret scale [J].
Brehaut, JC ;
O'Connor, AM ;
Wood, TJ ;
Hack, TF ;
Siminoff, L ;
Gordon, E ;
Feldman-Stewart, D .
MEDICAL DECISION MAKING, 2003, 23 (04) :281-292
[3]   INFORMED CONSENT - WHY ARE ITS GOALS IMPERFECTLY REALIZED [J].
CASSILETH, BR ;
ZUPKIS, RV ;
SUTTONSMITH, K ;
MARCH, V .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 302 (16) :896-900
[4]   Living with treatment decisions: Regrets and quality of life among men treated for metastatic prostate cancer [J].
Clark, JA ;
Wray, NP ;
Ashton, CM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :72-80
[5]  
Coulter A, 1997, J Health Serv Res Policy, V2, P112
[6]   Informed consent and decision-making: patients' experiences of the process of recruitment to phases I and II anti-cancer drug trials [J].
Cox, K .
PATIENT EDUCATION AND COUNSELING, 2002, 46 (01) :31-38
[7]  
Cox K, 2000, PSYCHO-ONCOL, V9, P314, DOI 10.1002/1099-1611(200007/08)9:4<314::AID-PON464>3.0.CO
[8]  
2-C
[9]   Psychosocial aspects of participation in early anticancer drug trials - Report of a pilot study [J].
Cox, K ;
Avis, M .
CANCER NURSING, 1996, 19 (03) :177-186
[10]   Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: A study of the eastern cooperative oncology group [J].
Coyne, CA ;
Xu, RH ;
Raich, P ;
Plomer, K ;
Dignan, M ;
Wenzel, LB ;
Fairclough, D ;
Habermann, T ;
Schnell, L ;
Quella, S ;
Cella, D .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) :836-842